Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA.
Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, CA.
Urology. 2014 Jan;83(1):159-65. doi: 10.1016/j.urology.2013.08.074. Epub 2013 Nov 12.
To describe 3 cases of advanced refractory penile cancer treated with targeted therapy against the epidermal growth factor receptor (EGFR).
We identified 3 patients with advanced penile cancer who had disease progression after platinum chemotherapy refractory and who subsequently received EGFR-targeted therapy. Their tumor tissue was evaluated for expression of EGFR by immunohistochemistry and messenger ribonucleic acid quantitation and was also tested for the presence of human papillomavirus deoxyribonucleic acid by line hybridization. K-ras mutation was evaluated by polymerase chain reaction for 6 mutations in codon 12 and 1 mutation in codon 13.
One patient responded to cetuximab and remains disease-free 42 months after presentation. One patient responded to panitumumab, then suffered relapse. One other progressed through EGFR-targeted therapy. EGFR expression by immunohistochemistry was 1-2+ in all cases, and messenger ribonucleic acid expression ranged from 4.08 to 7.33. No K-ras mutations or human papillomavirus deoxyribonucleic acid was detected.
We report 3 cases in which EGFR-targeted therapy was used to treat platinum-refractory penile cancer patients. Because 2 of the 3 had clinical benefit, future prospective trials of EGFR-targeted therapy in penile cancer are warranted.
描述 3 例接受表皮生长因子受体（EGFR）靶向治疗的晚期难治性阴茎癌病例。
我们鉴定了 3 例晚期阴茎癌患者，这些患者在铂类化疗耐药后疾病进展，随后接受了 EGFR 靶向治疗。通过免疫组织化学和信使核糖核酸定量评估肿瘤组织中 EGFR 的表达，并通过线杂交检测人乳头瘤病毒脱氧核糖核酸的存在。通过聚合酶链反应评估 K-ras 突变，以检测密码子 12 中的 6 个突变和密码子 13 中的 1 个突变。
1 例患者对西妥昔单抗有反应，在出现症状后 42 个月仍无疾病。1 例患者对帕尼单抗有反应，然后复发。另 1 例患者通过 EGFR 靶向治疗进展。所有病例的 EGFR 免疫组织化学表达为 1-2+，信使核糖核酸表达范围为 4.08-7.33。未检测到 K-ras 突变或人乳头瘤病毒脱氧核糖核酸。
我们报告了 3 例接受 EGFR 靶向治疗的铂类难治性阴茎癌患者。由于其中 2 例有临床获益，因此有必要在未来开展针对阴茎癌的 EGFR 靶向治疗的前瞻性试验。
